CEACAM5 and ovarian cancer: PSA, cancer antigen (CA) 19-9, carcinoembryonic antigen (CEA), and CA-125 are protein biomarkers currently used to help detect malignancy and assess a therapeutic response in prostate, pancreatic, gastrointestinal, and ovarian cancers, respectively.